Cochlear (ASX:COH) was upgraded by equities researchers at Deutsche Bank to a “buy” rating in a report released on Thursday.
Separately, Jefferies Financial Group set a $53.00 price objective on Cochlear and gave the stock a “buy” rating in a report on Thursday.
COH stock opened at A$166.03 ($117.75) on Thursday. The company has a debt-to-equity ratio of 24.18, a quick ratio of 1.35 and a current ratio of 2.03. Cochlear has a 52-week low of A$129.18 ($91.62) and a 52-week high of A$192.80 ($136.74).
Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers cochlear implants, including Nucleus 7 and Kanso sound processors; Carina middle-ear implants and accessories; and Baha bone conduction implants, such as Baha attract system, Baha connect system, Baha softband, Baha 5 sound processor, Baha 5 power, Baha 5 superpower, other sound processors, and wireless accessories.
Featured Story: What is a stock split?
Receive News & Ratings for Cochlear Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cochlear and related companies with MarketBeat.com's FREE daily email newsletter.